S&P 500 7,609.78 +0.13% NASDAQ 27,093.90 +0.03% DOW 51,307.79 +0.45% R2K 2,931.96 +0.90% VIX 15.77 -1.74%
Next Bullish Trade
MRK Merck & Co., Inc. NYQ
$115.65 +0.48 (+0.42%)
Neutral · -0.08σ
+ Compare Set alert Open in Sniper

Price chart

Overlay: Click earnings ▲ markers for day-move details

Loading 1Y daily…

Financial overlay · last 12 quarters

QuarterRevenue Net incomeOp income FCFNet margin Op margin
2026-03-31 $16.3B $-4.2B $-3.2B $2.9B -26.0% -19.7%
2025-12-31 $16.4B $3.0B $4.1B $1.8B 18.1% 24.8%
2025-09-30 $17.3B $5.8B $6.6B $6.8B 33.5% 37.9%
2025-06-30 $15.8B $4.4B $5.6B $2.5B 28.0% 35.1%
2025-03-31 $15.5B $5.1B $5.9B $1.2B 32.7% 38.2%
2024-12-31 $nanB $nanB $nanB $nanB nan% nan%

Earnings replay · last 20 reports

DateEPS actual EPS estSurprise
2026-04-30 -1.28 -1.47 +13.2%
2026-02-03 1.19 1.68 -29.2%
2025-10-30 2.32 2.06 +12.8%
2025-07-29 2.13 2.03 +5.0%
2025-04-24 2.22 2.14 +4.0%
2025-02-04 1.72 1.67 +3.3%
2024-10-31 1.57 1.57 +0.0%
2024-07-30 2.28 2.14 +6.3%
2024-04-25 2.07 1.92 +7.7%
2024-02-01 0.03 -0.11 +127.5%
2023-10-26 2.13 1.95 +9.5%
2023-08-01 -2.06 -2.18 +5.4%
2023-04-27 1.40 1.34 +4.8%
2023-02-02 1.62 1.54 +5.4%
2022-10-27 1.85 1.71 +8.3%
2022-07-28 1.87 1.71 +9.6%
2022-04-28 2.14 1.83 +17.1%
2022-02-03 1.80 1.52 +18.1%
2021-10-28 1.75 1.55 +12.6%
2021-07-29 1.31 1.35 -2.9%

Earnings markers are overlaid on the price chart above. Transcript summaries require PERPLEXITY_API_KEY (deferred to a follow-up).

Peer comparison · Healthcare

Ticker ⇅ Mkt cap ⇅ P/E ⇅ Fwd P/E ⇅ P/S ⇅ EV/EBITDA ⇅ P/B ⇅ Gross M ⇅ Rev gr ⇅ EPS gr ⇅ FCF yld ⇅
LLY $949B 37.7 23.9 13.1 27.3 30.5 82.8% 55.5% 169.9% 0.96%
UNH $343B 28.5 18.1 0.8 18.5 3.5 18.8% 2.0% 0.7% 5.15%
JNJ $537B 25.8 17.5 5.6 16.6 6.6 68.0% 9.9% -52.9% 2.33%
MRK ★ $286B 32.6 12.1 4.3 11.2 6.2 76.7% 4.9% — 4.92%
ABBV $381B 105.1 13.3 6.1 14.8 -57.2 72.0% 12.4% -46.2% 5.47%
PFE $146B 19.5 9.0 2.3 7.8 1.6 74.8% 5.4% -10.1% 8.50%
TMO $179B 26.5 17.7 4.0 19.4 3.4 40.9% 6.2% 11.3% 3.08%
ABT $151B 24.4 14.3 3.4 15.2 2.9 56.5% 7.8% -19.7% 4.19%

Auto-seeded from sector. Click any ticker to switch.

Ownership

Top institutional holders

Top-10 concentration: 36.92%

HolderShares% out
Blackrock Inc. 225,830,330 9.14%
Vanguard Capital Management LLC 160,987,624 6.52%
State Street Corporation 119,325,673 4.83%
Wellington Management Group, LLP 84,314,971 3.41%
Vanguard Portfolio Management LLC 67,304,305 2.73%
Geode Capital Management, LLC 59,558,154 2.41%
JPMORGAN CHASE & CO 52,972,983 2.14%
Charles Schwab Investment Management 49,765,225 2.01%
Morgan Stanley 47,632,487 1.93%
FMR, LLC 44,516,010 1.80%

Insider activity · 90d

No insider trades for MRK in last 90d.

Analyst estimates

yfinance
Low
$100.0
Mean
$129.74074
High
$150.0
Analysts
27

Consensus: buy (mean 1.82759). Distribution requires FINNHUB_API_KEY.

SEC filings

FormFiled DescriptionAction
4 2026-06-02 PRIMARY DOCUMENT view ·
4 2026-06-02 PRIMARY DOCUMENT view ·
4 2026-06-02 PRIMARY DOCUMENT view ·
4 2026-06-02 PRIMARY DOCUMENT view ·
4 2026-06-02 PRIMARY DOCUMENT view ·
4 2026-06-02 PRIMARY DOCUMENT view ·
4 2026-06-02 PRIMARY DOCUMENT view ·
4 2026-06-02 PRIMARY DOCUMENT view ·
4 2026-06-02 PRIMARY DOCUMENT view ·
4 2026-06-02 PRIMARY DOCUMENT view ·
4 2026-06-02 PRIMARY DOCUMENT view ·
4 2026-06-02 PRIMARY DOCUMENT view ·
8-K 2026-05-28 FORM 8-K view ·
8-K 2026-05-22 8-K view ·
13F-HR 2026-05-13 Institutional holdings (13F) view ·
4 2026-05-07 PRIMARY DOCUMENT view ·
4 2026-05-07 PRIMARY DOCUMENT view ·
4 2026-05-07 PRIMARY DOCUMENT view ·
4 2026-05-07 PRIMARY DOCUMENT view ·
4 2026-05-07 PRIMARY DOCUMENT view ·
4 2026-05-07 PRIMARY DOCUMENT view ·
4 2026-05-07 PRIMARY DOCUMENT view ·
4 2026-05-07 PRIMARY DOCUMENT view ·
4 2026-05-07 PRIMARY DOCUMENT view ·
4 2026-05-07 PRIMARY DOCUMENT view ·
4 2026-05-07 PRIMARY DOCUMENT view ·
4 2026-05-07 PRIMARY DOCUMENT view ·
4 2026-05-05 PRIMARY DOCUMENT view ·
4 2026-05-05 PRIMARY DOCUMENT view ·
10-Q 2026-05-04 1Q26 FORM 10-Q view ·
4 2026-05-01 PRIMARY DOCUMENT view ·
4 2026-05-01 PRIMARY DOCUMENT view ·
4 2026-05-01 PRIMARY DOCUMENT view ·
4 2026-05-01 PRIMARY DOCUMENT view ·
4 2026-05-01 PRIMARY DOCUMENT view ·
4 2026-05-01 PRIMARY DOCUMENT view ·
4 2026-05-01 PRIMARY DOCUMENT view ·
4 2026-05-01 PRIMARY DOCUMENT view ·
4 2026-05-01 PRIMARY DOCUMENT view ·
4 2026-05-01 PRIMARY DOCUMENT view ·
4 2026-05-01 PRIMARY DOCUMENT view ·
8-K 2026-04-30 FORM 8-K view ·
DEF 14A 2026-04-08 DEF 14A view ·
4 2026-04-01 PRIMARY DOCUMENT view ·
4 2026-04-01 PRIMARY DOCUMENT view ·
4 2026-04-01 PRIMARY DOCUMENT view ·
10-K 2026-02-24 10-K FOR THE FISCAL YEAR ENDED DECEMBER 31, 2025 view ·
13F-HR 2026-02-17 Institutional holdings (13F) view ·
4 2026-02-12 PRIMARY DOCUMENT view ·
4 2026-02-10 PRIMARY DOCUMENT view ·
4 2026-02-09 PRIMARY DOCUMENT view ·
4 2026-02-09 PRIMARY DOCUMENT view ·
4 2026-02-06 PRIMARY DOCUMENT view ·
4 2026-02-06 PRIMARY DOCUMENT view ·
4 2026-02-06 PRIMARY DOCUMENT view ·
4 2026-02-06 PRIMARY DOCUMENT view ·
4 2026-02-06 PRIMARY DOCUMENT view ·
4 2026-02-06 PRIMARY DOCUMENT view ·
4 2026-02-06 PRIMARY DOCUMENT view ·
4 2026-02-06 PRIMARY DOCUMENT view ·

About

Merck & Co., Inc. operates as a healthcare company worldwide. It offers human health pharmaceutical for various areas under the Keytruda, Keytruda Qlex, Welireg, Gardasil, ProQuad, M-M-R II, Varivax, Vaxneuvance, Capvaxive, RotaTeq, Pneumovax 23, Bridion, Prevymis, Dificid, Zerbaxa, Winrevair, Adempas/ Verquvo, Ohtuvayre, Lagevrio, Isentress/Isentress HD, Delstrigo, Pifeltro, Belsomra, Januvia, and Janumet brands. The company also provides veterinary pharmaceuticals, vaccines and health management solutions and services, such as livestock products under the Nuflor, Bovilis/Vista, Bovilis Cryptium, Banamine, Estrumate, Matrix, Resflor, Zuprevo, Revalor, Safe-Guard, M+Pac, Porcilis, Circumvent, Nobilis/Innovax, Paracox and Coccivac, Exzolt, Slice, Imvixa, Clynav, Aquavac/Norvax, Aquaflor, Flexolt brands; Allflex Livestock Intelligence solutions; and companion animal products under the Bravecto One-Month, Bravecto Injectable/Quantum, Bravecto TriUNO, Bravecto Plus, Sentinel Spectrum, Sentinel Flavor Tabs, Numelvi, Optimmune, Nobivac NXT, GilvetMab, Otomax, Mometamax, Mometamax Ultra, Posatex, Caninsulin/Vetsulin, Panacur, Safeguard, Regumate, Prestige, Scalibor/Exspot, Sure Petcare, a…